Coronary Microvascular Dysfunction in Men: The Cardiac Risk That Hides Behind Normal Arteries

When the Angiogram Is Normal but the Problem Is Not

A man in his mid-fifties presents with exertional chest pressure that has been building for three months. His stress test is positive. He is taken to the catheterization laboratory, and the interventional cardiologist finds clean coronary arteries. He is told he is fine. He is sent home on no new medications.

He is not fine.

What this man likely has is coronary microvascular dysfunction (CMD), a condition that affects the smallest arteries and capillaries of the heart, vessels too small to be seen on a standard angiogram. The evidence shows CMD is present in a substantial proportion of men investigated for chest pain who turn out to have no obstructive coronary artery disease. For decades, these patients fell into a diagnostic void. That void is now closing, but only slowly, and only for those whose cardiologists know to look.

What Coronary Microvascular Dysfunction Actually Is

The coronary circulation has two functional compartments. The epicardial arteries, visible on angiogram, serve as conduits. The microvasculature, comprising arterioles, capillaries, and venules smaller than 500 microns in diameter, regulates blood flow delivery to heart muscle based on metabolic demand. This regulatory function depends on a coordinated interplay of endothelium-derived vasodilators (primarily nitric oxide), smooth muscle tone, autonomic signaling, and structural vessel integrity.

CMD is defined as impaired microvascular vasodilation and/or increased microvascular resistance that causes myocardial ischemia. The result is the same as obstructive disease in terms of symptoms and, in many cases, prognosis: inadequate oxygen delivery to heart muscle during periods of demand. The fundamental difference is that the obstruction is not a plaque in a large artery. It is diffuse, structural, and functional dysfunction distributed throughout a vascular bed that no catheter can reach directly.

Several distinct mechanisms contribute. Endothelial dysfunction reduces nitric oxide bioavailability, impairing flow-mediated vasodilation. Smooth muscle dysfunction causes abnormal vasoconstriction responses. Structural remodeling, including rarefaction (loss of vessel density), wall thickening, and perivascular fibrosis, reduces the total cross-sectional area available for perfusion. In some patients, all three mechanisms operate simultaneously.

How Men’s CMD Differs from Women’s

CMD research historically focused on women, particularly in the context of ischemia with no obstructive coronary artery disease (INOCA). Women are more likely to present with isolated CMD in the absence of epicardial disease. Men, by contrast, more commonly present with CMD as a co-existing pathology layered on top of obstructive coronary artery disease.

This distinction matters clinically. Men with CMD alone have a measurably elevated cardiovascular risk compared to healthy controls, but men with CMD combined with obstructive CAD represent a particularly high-risk phenotype. The microvascular disease compounds the ischemic burden from the epicardial lesions, undermines collateral flow, and predicts worse outcomes after revascularization. In this population, fixing the obstructive lesion without addressing the microvascular dysfunction leaves a substantial residual problem.

Men in the post-percutaneous coronary intervention (PCI) setting are a specific concern. Up to 50% of men undergoing primary PCI for ST-elevation myocardial infarction (STEMI) demonstrate microvascular obstruction (MVO) on cardiac magnetic resonance imaging (CMR) performed within 48 hours of the procedure. MVO, sometimes called the no-reflow phenomenon, occurs when the epicardial vessel is successfully opened but downstream microvascular damage prevents tissue reperfusion. Myocytes in the territory remain ischemic despite a patent artery. CMR-detected MVO independently predicts left ventricular remodeling, heart failure, and mortality at follow-up. It is now recognized as a meaningful endpoint in STEMI clinical trials.

Risk Factors Driving CMD in Men

Certain conditions are particularly potent drivers of microvascular dysfunction in men.

Type 2 diabetes is the strongest single risk factor. The mechanisms are multiple and intersecting. Chronic hyperglycemia damages the endothelial glycocalyx, the thin protective layer lining microvascular walls, reducing the vessel’s ability to sense shear stress and generate protective nitric oxide. Pericyte loss, a hallmark of diabetic microvascular disease affecting the retina and kidney, also occurs in the coronary microvasculature. Advanced glycation end-products stiffen vessel walls and drive perivascular fibrosis. Men with type 2 diabetes have the highest CMD prevalence of any group studied, and many develop CMD before overt epicardial CAD is detectable.

Hypertension drives structural microvascular remodeling through different mechanisms. Sustained pressure overload causes inward eutrophic remodeling of arteriolar walls, reducing lumen-to-wall ratio. Over time, microvascular rarefaction occurs, meaning the absolute density of small vessels decreases. A heart supplied by fewer, stiffer microvasculature has reduced vasodilatory reserve even when epicardial vessels remain unobstructed. The contribution of hypertension to CMD is dose and duration dependent.

Smoking damages microvascular endothelial function acutely through oxidative stress and chronically through endothelial injury and accelerated atherogenesis extending into the microvasculature. Visceral obesity and insulin resistance, even in the absence of frank diabetes, impair nitric oxide bioavailability and promote a pro-inflammatory microvascular environment. In men with metabolic syndrome, CMD is frequently detectable before any symptoms appear.

Measuring What Cannot Be Seen: CFR and IMR

Because the microvasculature is not directly visible, diagnosing CMD requires functional assessment of microvascular performance.

Coronary flow reserve (CFR) is the primary metric. CFR is defined as the ratio of maximal coronary blood flow during hyperemia (achieved with adenosine or regadenoson) to resting coronary blood flow. In a healthy coronary microvascular system, maximal flow is at least three to four times resting flow. A CFR below 2.0 is considered abnormal and indicates significant microvascular dysfunction. CFR can be measured invasively with an intracoronary Doppler wire or thermodilution technique during cardiac catheterization. Non-invasive measurement is possible with stress positron emission tomography (PET) or stress cardiac magnetic resonance (CMR), both of which provide myocardial blood flow quantification.

Stress PET with rubidium-82 or nitrogen-13 ammonia offers high sensitivity for CMD detection and can map regional flow heterogeneity across all coronary territories simultaneously. In men with known or suspected CAD who have access to a PET center, stress PET provides both epicardial stenosis assessment and microvascular function data in a single study.

The index of microvascular resistance (IMR) is an invasive metric measured during cardiac catheterization. IMR is calculated from the distal coronary pressure and the mean transit time of a saline bolus during maximum hyperemia, without requiring a flow wire. IMR above 25 is defined as abnormal. IMR has particular value in the post-PCI setting. Measured immediately after primary PCI in men with STEMI, elevated IMR predicts persistent MVO on subsequent CMR and independently forecasts left ventricular function at six-month follow-up. Research from Fearon and colleagues (2013) established the prognostic significance of IMR in this context, providing interventional cardiologists with a real-time assessment tool during the index procedure.

The ISCHEMIA trial (2019), published by Maron and colleagues in the New England Journal of Medicine, enrolled over 5,000 patients with stable coronary artery disease and moderate to severe ischemia on stress testing. While the primary finding was the non-inferiority of conservative medical therapy versus routine revascularization for hard outcomes, the trial’s substudies and subsequent analyses identified CMD as independently present in a meaningful subset. CMD was associated with worse quality of life and independently predicted outcomes regardless of the revascularization strategy chosen.

The Diabetic Heart: A Special Case

Men with type 2 diabetes and CMD represent a distinct management challenge. HbA1c control slows the progression of microvascular damage but does not reverse established dysfunction. The clinical implication is that by the time CMD is diagnosed in a diabetic man, glycemic improvement alone is insufficient.

The evidence shows that newer glucose-lowering drug classes may improve microvascular function through mechanisms that go beyond blood sugar reduction. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce intracardiac inflammation, decrease pericardial fat, improve endothelial function, and reduce adverse remodeling. While randomized trials with CFR as a primary endpoint are limited, cardiovascular outcome trials have demonstrated mortality and heart failure hospitalization benefits that may partly reflect microvascular improvements. GLP-1 receptor agonists (semaglutide, liraglutide) reduce visceral adiposity and have demonstrated anti-inflammatory and endothelial-protective effects in preclinical and early human studies.

For men with diabetes, CMD, and no obstructive CAD, cardiologists increasingly consider initiating SGLT2 inhibitors or GLP-1 agonists as part of a comprehensive cardiovascular risk reduction strategy, even in the absence of traditional heart failure or post-MI indications.

Management: What Works and What Is Emerging

The therapeutic approach to CMD in men requires addressing both mechanisms and symptoms.

Renin-angiotensin system blockade with ACE inhibitors or ARBs improves endothelial function and reduces microvascular resistance through multiple pathways, including reduced angiotensin II-driven vasoconstriction, improved nitric oxide bioavailability, and reduced aldosterone-mediated fibrosis. In men with hypertension and CMD, renin-angiotensin system blockade serves dual purposes: blood pressure control and direct microvascular benefit. Some cardiologists also use ACE inhibitors in normotensive men with CMD and diabetes, given the established microvascular protective effects seen in renal disease, which shares mechanistic overlap with cardiac microvascular injury.

Statins exert pleiotropic benefits on the microvasculature beyond LDL reduction. High-intensity statin therapy improves endothelial function, reduces vascular inflammation, stabilizes glycocalyx integrity, and promotes nitric oxide bioavailability. In men with CMD and coexisting atherosclerotic risk factors, high-intensity statins are appropriate regardless of whether obstructive CAD is present.

Ranolazine, a late sodium channel inhibitor approved for chronic angina, has been studied specifically in CMD. Ranolazine reduces myocardial oxygen demand without reducing heart rate or blood pressure, and the evidence shows it improves diastolic function and reduces ischemia in patients with microvascular disease. Several cardiologists consider it for men with symptomatic CMD who have failed first-line therapies.

Beta-blockers reduce myocardial oxygen demand and extend diastolic perfusion time, both relevant to microvascular ischemia. They reduce anginal symptom burden in CMD and are appropriate in men with comorbid hypertension or post-MI status. However, in some CMD phenotypes characterized by vasospasm, beta-blockade may paradoxically increase resistance, and clinicians tailor drug selection accordingly.

Calcium channel blockers, particularly non-dihydropyridines like diltiazem or verapamil, reduce microvascular spasm and are used in men with evidence of vasospastic mechanisms contributing to CMD. Long-acting dihydropyridines (amlodipine) are an alternative in men who also need blood pressure reduction.

Emerging Intervention: The Coronary Sinus Reducer

For men with refractory microvascular angina who have not responded adequately to maximal medical therapy, an emerging device-based intervention is under evaluation. The coronary sinus reducer (Neovasc Reducer) is a stainless steel hourglass-shaped device implanted percutaneously into the coronary sinus. It partially narrows the coronary sinus, increasing venous backpressure, which redistributes blood flow from the epicardium toward the ischemia-prone subendocardium where microvascular dysfunction causes the most damage.

Early trials, primarily enrolling patients with refractory angina and CMD components, have shown improvements in quality of life, anginal class, and exercise tolerance. Men who failed multiple anti-anginal drugs and were not candidates for revascularization represent the target population. While evidence from large-scale randomized trials is still maturing, some centers now offer this procedure within a structured pathway for refractory CMD, reflecting its potential to address a condition that currently has few escalation options.

The Diagnostic Gap Clinicians Must Close

The core clinical problem is that CMD is invisible on angiography, and for most of the history of invasive cardiology, the angiogram was the endpoint of the diagnostic workup. A normal angiogram was equated with normal coronary function. That equivalence is now known to be wrong, and updated guidelines from the European Society of Cardiology and the American Heart Association increasingly recommend functional assessment of the microvasculature in patients with INOCA.

Men with persistent angina, positive stress tests, and non-obstructive coronaries deserve a structured second evaluation that includes CFR and IMR measurement. Those with CMD identified should be placed on evidence-based therapy, referred to cardiologists with specific CMD expertise, and followed with the same rigor applied to obstructive CAD. The prognosis of untreated CMD is not benign, particularly in men with diabetes or post-MI microvascular obstruction, and the field is moving toward treating it with the same seriousness as epicardial disease.

Recognizing CMD in Practice

The clinical presentation of CMD in men is frequently indistinguishable from obstructive CAD. Exertional chest pressure is the most common symptom. Some men describe effort-induced fatigue or dyspnea without chest pain, reflecting subendocardial ischemia that does not produce classic anginal patterns. Symptoms are often worse after meals (due to postprandial steal) and in the early morning hours when vasomotor tone is highest.

ECG stress testing in CMD often produces equivocal or mildly positive results, not the dramatic ST depressions seen in proximal LAD disease. Nuclear perfusion imaging may show mild or diffuse perfusion heterogeneity rather than a discrete territorial defect. Cardiologists familiar with CMD recognize these patterns as consistent with microvascular dysfunction rather than dismissing them as false-positive results.

A systematic approach to the man with suspected CMD includes a careful history of symptom triggers and quality, assessment of CMD risk factors (particularly diabetes and hypertension duration), resting echocardiography to assess for wall motion abnormalities and diastolic dysfunction (which frequently accompanies CMD), and a decision on whether non-invasive CFR measurement via stress PET or invasive assessment via catheterization is the appropriate next step.

Understanding CMD as a distinct pathophysiological entity, rather than a residual category for patients who “came back normal,” represents a meaningful shift in how cardiology approaches chest pain in men. The tools to make the diagnosis exist. Using them is now a matter of clinical will and system-level awareness.

The Role of Diastolic Dysfunction in CMD

A finding that frequently accompanies CMD in men is diastolic dysfunction, impaired relaxation of the left ventricle during filling. Diastolic dysfunction arises from the same pathological processes that drive CMD: myocardial fibrosis, microvascular rarefaction, hypertensive remodeling, and reduced nitric oxide-mediated coronary vasomotion. The two conditions are not merely co-incidental; they share mechanistic roots and amplify each other’s clinical effects.

Men with CMD and concurrent diastolic dysfunction experience exertional dyspnea that is disproportionate to the degree of angina, because the stiff, poorly relaxing left ventricle cannot accommodate the increased venous return that exercise demands. This dyspnea-dominant presentation is sometimes labeled heart failure with preserved ejection fraction (HFpEF), and the overlap between CMD and HFpEF is now recognized as one of the major unresolved challenges in heart failure research. Many cardiologists consider CMD a component of HFpEF pathophysiology rather than a separate entity in men with both conditions present.

On resting echocardiography, diastolic dysfunction in CMD-affected men is detected through mitral inflow patterns, tissue Doppler of the medial mitral annulus, and left atrial volume index. An elevated E/e’ ratio, a validated surrogate for left ventricular filling pressure, is a common finding. Identifying diastolic dysfunction in a man with INOCA strengthens the diagnostic case for CMD and adds prognostic weight that should inform treatment intensity.

Sex-Specific Physiology: Why Men Require Different Testing Thresholds

The diagnostic thresholds for CMD were derived in mixed or predominantly female populations, and the evidence shows that men may have inherently higher resting coronary blood flow and different CFR distributions than women at equivalent ages. This means that a CFR of 2.2 in a man in his sixties with diabetes and multiple risk factors may represent meaningful dysfunction even if it nominally exceeds the 2.0 cutoff.

Fractional flow reserve (FFR), the standard tool for assessing epicardial stenosis significance during catheterization, does not capture microvascular dysfunction. A man with an FFR of 0.85 in a 60% LAD stenosis and a concurrent IMR of 32 has both epicardial and microvascular disease. Treating only the epicardial stenosis and calling the procedure complete leaves the microvascular component unaddressed and the man at elevated residual risk. Newer combined physiological assessments performed during the same catheterization procedure, including simultaneous FFR and CFR measurement, are increasingly used in specialized centers to characterize the full hemodynamic picture.

Monitoring and Follow-Up in Men with Established CMD

Men diagnosed with CMD require structured follow-up that differs from standard CAD surveillance. Because the condition is not amenable to the anatomic endpoints used in obstructive CAD (such as repeat angiography or fractional flow reserve), functional endpoints take precedence. Serial assessment of anginal burden using validated tools such as the Seattle Angina Questionnaire, exercise capacity measured by treadmill or metabolic stress testing, and echocardiographic diastolic parameters provides a longitudinal picture of disease progression or stabilization.

Risk factor control intensity is directly related to CMD outcomes in men. Sustained blood pressure below 130/80 mmHg, LDL below 70 mg/dL, HbA1c below 7% in diabetic men, and smoking cessation together constitute the modifiable target profile. Some cardiologists use annual stress PET in men with CMD and multiple risk factors to monitor absolute myocardial blood flow over time, using quantitative PET as a direct measure of microvascular function that tracks response to therapy.

The frequency of follow-up visits should reflect the CMD severity, symptom burden, and presence of comorbidities. Men with CMD and well-controlled risk factors who are asymptomatic on optimal medical therapy may be managed with annual cardiology review. Those with refractory angina, progressive symptoms, or new diastolic dysfunction warrant more frequent reassessment.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.